Cereno Scientific investor relations material

Cereno Scientific AB (publ), a clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. The company is involved in developing CER-001, which is in Phase IIa study for the treatment of acute reperfused myocardial infarction; and Phase I/II study for amyotrophic lateral sclerosis patients. It has a collaboration with Oxford BioTherapeutics Ltd. to further advance the clinical development of CER-001 for the treatment of acute myocardial infarction; and strategic alliance with Novartis to develop tissue agnostic therapeutic treatments.